Portal de Periódicos da CAPES

Manufacturing Process Development for Belzutifan, Part 2: A Continuous Flow Visible-Light-Induced Benzylic Bromination

2021; American Chemical Society; Volume: 26; Issue: 3 Linguagem: Inglês

10.1021/acs.oprd.1c00240

1520-586X

Cecilia Bottecchia, François Lévesque, Jonathan P. McMullen, Yining Ji, Mikhail Reibarkh, Feng Peng, Lushi Tan, Glenn Spencer, Jarod Nappi, Dan Lehnherr, Karthik Narsimhan, Michael K. Wismer, Like Chen, Yipeng Lin, Stephen M. Dalby,

Nanomaterials for catalytic reactions

We report the development and scale-up of a continuous flow photochemical benzylic bromination en route to belzutifan (MK-6482), a small molecule for the treatment of renal cell carcinoma associated with Von Hippel–Lindau syndrome. Compared with the clinical supply route, the photochemical approach circumvents the need for azo radical initiators and proceeds at room temperature. Implementation of continuous flow technology allowed tight control of irradiation and residence time, resulting in a robust process with minimized byproduct formation. This method was selected for the manufacturing process for belzutifan and represents the first commercial continuous flow photochemical process in our company, laying the foundation for the utilization of photochemistry in the pharmaceutical industry.